

March 12, 2024

Mr. John Crowley
President and CEO
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300
Washington, DC 20005

Dear Mr. Crowley:

The Biotechnology Innovation Organization (BIO) serves an essential role in advocating for stakeholders throughout the biotechnology industry. Since its founding, BIO has ensured that America's interests are advanced by a strong, vibrant and diverse array of companies that are supported by partners worldwide. Respectfully and regrettably, however, I am writing to inform you that, effective immediately, WuXi AppTec, along with our subsidiary WuXi Clinical, will end our associate membership in BIO.

In recent weeks, WuXi AppTec has become the target of U.S. legislative efforts that preemptively and unfairly target our company without due process, a transparent review of the facts, or consideration of their impact on U.S. leadership in biotechnology innovation and patient care. These misinformed efforts, which recently extended to maligning our membership in BIO, risk distracting from the important and honorable work of BIO to represent the biotechnology industry and its vital role in delivering safe and effective treatments to patients in need.

WuXi AppTec has always been guided by our core value of "doing the right thing and doing it right." Our company has never been subject to U.S. sanctions or determined by any federal government agency to pose a national security risk to the United States. In fact, WuXi AppTec respects and fully complies with the strict reporting, oversight and/or inspection requirements of multiple U.S. federal and state government authorities and our customers, and we are proud of this strong track record of compliance and successful audits. We believe that a voluntary separation from BIO at this time will allow BIO to continue focusing on educating policymakers, raising awareness among the public, and advocating for the industry – which, as this episode demonstrates, is of critical importance.

For more than 20 years, WuXi AppTec has enabled thousands of companies across the pharmaceutical and life sciences industries to discover, develop, and manufacture new medicines to benefit patients. We remain committed to our vision of "every drug can be made and every disease can be treated," and will continue to advance our highest priority of providing the quality service that our customers and partners have always expected from WuXi AppTec.

I wish you and BIO well in your future endeavors.

Sincerely,

Richard D. Connell

Richard D. Connell, Ph.D.
Senior Vice President
Chief Operating Officer for the U.S. & Europe